Hanson Wade Group’s Post

A major challenge faced in the field of biologics drug discovery is the long and labor-intensive workflows needed for identification and validation of potential therapeutics. Enter our WAVEsystem. Designed to support life science researchers, the WAVEsystem is a game-changer in accelerating drug discovery processes. Curious to dive deeper into what the WAVEsystem offers? Our upcoming webinar ‘Measuring binding kinetics in complex samples to support biologics development’ might just be what you’re looking for! In this webinar, you’ll discover the importance of reliable molecular binding characterization. You’ll understand how the WAVEsystem combines high sensitivity and signal stability, and you’ll learn how no-clog microfluidics allows you to measure binding kinetics in complex samples with less device downtime. Does this pique your interest? You can sign up for the webinar here 👉 https://bit.ly/3Rg6sUE 📅 29 November 🕙 09:00 GMT / 10:00 CET / 04:00 EST / 01:00 PST / 17:00 Shanghai #webinar #wavesystem #bindingkinetics #drugdiscovery

Zimple Matharu, PhD, from NGM Biopharmaceuticals gave a stellar talk at the Festival of Biologics meeting in San Diego this week. Nice work Zimple! Her talk focused on antibody characterization and utilizing Carterra's HT-SPR label-free technology and Epitope software capabilities to uncover epitope diversity. Looking at the results, one can see why understanding epitope diversity earlier in the process using the LSA's high definition data is so powerful.

WRIB (Workshops on Recent Issues in Bioanalysis) empowers drug developers to optimize their bioanalytical strategies. Meet Sannova at booth # 56. DM our team for more details. WRIB lets drug developers engage in discussions on optimal bioanalytical methods and gain insights from regulatory experts. Visit Sannova at booth # 56 to explore our exceptional ISR pass rates and discover how our advanced equipment adds precision to your regulatory submissions. #WRIB2024 #BioanalyticalServices #Therapeutics #WRIBConference

Interesting article about using CD8 ImmunoPET to image and provide in vivo mapping of the CD8+ cellular response in early phase #clinicaltrials !

We are thrilled to announce today that the first patient has been dosed in BridGene's Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through its cutting-edge chemoproteomic platform, IMTAC™. This milestone highlights the potential of BridGene’s innovative chemoproteomics approach. Our breakthrough in developing covalent small molecule drugs for “hard-to-drug” targets marks a significant advancement in our mission to bring new therapies to patients. We thank everyone who has worked so hard to make this possible. Thank you for being a part of our journey! Read more here: https://lnkd.in/gJUAfAr7 #Biotech #Pharma #ClinicalTrials #DrugDevelopment #TEADInhibitor #Chemoproteomics #Innovation #CovalentDrugs #HardToDrugTargets #IMTAC #BridGene #Healthcare #MedicalResearch #Biotechnology #NewTherapies #FirstPatientDosed #FirstPatientIn #ClinicalTrialMilestone #PatientEnrollment #PatientFirst #ClinicalTrialProgress #MedicalBreakthrough #PatientJourney #ResearchMilestone #TrialParticipant #PatientSuccess

Thoughts on this? >> Editas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE program >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #biotech #healthcare

Today, we are excited to announce an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG). This new collaboration builds upon the partnership initiated in January 2024, focusing on the discovery of a highly selective oral SMARCA2 small molecule proteolysis targeting chimera (PROTAC). Under the expanded agreement, BridGene will leverage its PROTAC discovery engine in combination with Galapagos' expertise in selective ATPase small molecules. The collaboration aims to advance the molecule into a preclinical candidate, with Galapagos holding exclusive rights for further development and commercialization. Galapagos will provide BridGene with upfront and preclinical milestone payments, alongside additional payments based on clinical and commercial milestones, potentially bringing the total deal value to $159 million. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Read more here: https://lnkd.in/g7NyGm-m #BridGeneBiosciences #GalapagosNV #StrategicCollaboration #PrecisionOncology #PROTAC #SMARCA2 #DrugDiscovery #OncologyResearch #BiotechPartnership #InnovativeMedicine #CancerTreatment #TargetedTherapy #ClinicalResearch #Chemoproteomics #Biotechnology #Pharmaceuticals #DrugDevelopment #SmallMoleculeDrugs #ProteinDegradation #BiotechNews

In this collaboratively written op-ed article written together with Tracer CRO, read about recent trends in molecular imaging and drug development. Also, learn more about CD8 ImmunoPET™ imaging and Phase 0 clinical trials. Click here to read the article: https://buff.ly/3SolbNu Reach out to us to learn more about CD8 imaging in clinical trials at [email protected] #Biotech #Immunooncology #Clinicaltrials #pharmaceuticals #drugdevelopment #molecularimaging #CD8